At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 68 enrolled
Drug / intervention
Dasatinib (BMS-354825)drug
Likely dose
Dasatinib (BMS-354825) 70 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Therapy of Myeloid Metaplasia-Myelofibrosis, Atypical Chronic Myeloid or Myelomonocytic Leukemia, C-Kit Positive Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (AML-MDS), Hypereosinophilic Syndrome, Polycythemia Vera, and Mastocytosis With Dasatinib (BMS-354825)
In Brief
A Phase 2 clinical trial evaluating Dasatinib (BMS-354825) for Acute Myeloid Leukemia and 7 related conditions. Completed, enrolled 68 participants across 1 site.
Detailed Summary
The goal of this clinical research study is to learn if dasatinib can help to control myeloproliferative disorders. The safety and tolerability of dasatinib will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia, Myelodysplastic Syndromes, Agnogenic Myeloid Metaplasia, Myelofibrosis, Hypereosinophilic Syndrome, Polycythemia Vera, Mastocytosis, Leukemia, Myelomonocytic, Chronic
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2005
First PostedNov 2005
Primary CompletionMar 2017
TodayJul 2026
First PostedNov 18, 2005
Enrollment StartNov 15, 2005
Primary CompletionMar 3, 2017
TodayJul 2, 2026
Enrollment to primary: 11.3 yearsPosted 20.6 years ago
Interventions
Dasatinib (BMS-354825)drug
70 mg orally twice daily